BLUETTI
21.2.2024 06:25:27 CET | Business Wire | Press release
BLUETTI, a leading innovator in green energy storage solutions, announces the official launch of its ground-breaking SwapSolar ecosystem on Indiegogo on February 21 at CET 3 pm. Debuted at CES 2024, SwapSolar introduces the world's first LFP-powered MultiCooler portable fridge and the AC180T hot-swappable battery power station, redefining convenience and functionality for outdoor enthusiasts.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240220126870/en/
BLUETTI SwapSolar (Photo: Business Wire)
James Ray, BLUETTI's spokesperson, captures the essence of SwapSolar: "We want users to savor the joy of outdoor life. SwapSolar is your ticket to 3-6 days of happy camping trip. Power up and keep your food fresh, it's time to go wild with BLUETTI!”
BLUETTI MultiCooler: 3-in-1 Portable Fridge
The MultiCooler is a versatile appliance that combines ice-making, refrigeration, and freezing in one sleek design. With a temperature range of -20℃ to +20℃ and a capacity of 40L , it covers various refrigeration needs. The powerful compressor provides rapid cooling from 30℃ to 0℃ in just 15 minutes, complemented by a built-in ice maker for crystal-clear cubes in minutes.
The MultiCooler weighs approximately 25kg with wheels and a drawbar for effortless transport. It operates quietly at 30 dB and supports Bluetooth connectivity for remote control. With four charging methods, including wall outlets, vehicles, solar panels, and the AC180T’s battery(lasting for 3 days per pack), the MultiCooler ensures constant cooling on the go.
BLUETTI AC180T: Hot-Swappable Battery Power Station
The AC180T introduces a removable battery design that allows users to easily replace its two 716,8Wh LFP batteries. It can operate with either one or two batteries, while its power and charging vary accordingly.
Users can customize their power needs anytime by purchasing additional battery packs. The AC180T can provide 1.800W of power for most devices and supports fast 1.440W AC charging and solar charging for quick refreshment.
Pricing and Availability
BLUETTI offers a 5-year warranty for the AC180T and a 2-year warranty for the MultiCooler. Join the Indiegogo campaign starting February 21 at CET 3 pm to enjoy the best Super Early Bird offers on limited quantities.
About BLUETTI
Committed to a sustainable future, BLUETTI provides affordable green energy storage solutions for both indoor and outdoor use. With a diverse product portfolio tailored for adventures, emergency backup power, and off-grid living, BLUETTI is an industry leader present in 100+ countries, trusted by millions of customers worldwide.
Source: BLUETTI EU Marketing
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240220126870/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom